Gland Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.3 pts more than Nifty Smallcap 250 and 1.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Gland Pharma reported consolidated revenue of ₹15,056 million for Q1FY26, up 7% year-on-year from ₹14,017 million in Q1FY25. Profit after tax surged 50% YoY to ₹2,155 million (PAT margin expanded to 14% from 10%), while EBITDA grew 39% YoY to ₹3,678 million with margins improving to 24% from 19%. On a standalone basis, revenue rose to ₹10,388 million and PAT climbed about 21% YoY to ₹2,693 million. Growth was led by Europe (+29%) and Canada/Australia/NZ (+65%), while the USA market dipped 2%. European subsidiary Cenexi turned in an EBITDA breakeven of €0.9 million versus a €3 million loss a year ago, helped by cost optimisation and new tech-transfer products. The auditor Deloitte Haskins & Sells issued an unmodified (clean) limited review report.
Strong margin expansion and PAT growth should be viewed positively by investors, signalling improving profitability and a turnaround at the loss-making Cenexi unit. However, the slight revenue dip in the key USA market warrants monitoring. Overall, the print is supportive for the stock in the near term.